A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)
• Adults aged 40 to 80 years
• Post-BD spirometry at screening FEV1/FVC \< 0.70 and FEV1 30-80% predicted
• On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months
• Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months
• Elevated eosinophil count
• Weight/BMI within allowed range